Two-year outcome of patients treated with the zotarolimus-eluting (Endeavor) stent at a tertiary medical center
Background The Endeavor (Medtronic) zotarolimus-eluting stent (ZES) has shown favorable results in reducing target lesion revascularization (TLR) and vessel failure (TVF) in several registries and randomized trials. We report our…